Thalia Therapeutics plc (AIM:THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease is pleased to announce the acquisition, conditional upon shareholder approval, of Sanmirna Therapeutics, Inc. (“Sanmirna”), a US Corporation which holds an exclusive licence for the intellectual property and know-how around miRisten an anti-microRNA-126 for the treatment of Acute Myeloid Leukaemia, for an initial consideration of £3.675 million (the “Initial Consideration”) with deferred milestone payments worth up to an additional £13 million (the “Deferred Consideration”) (the “Acquisition”).
Read the full article: Thalia Therapeutics PLC Announces Acquisition //
Source: https://www.accessnewswire.com/newsroom/en/biotechnology/thalia-therapeutics-plc-announces-acquisition-and-%c2%a32.75-million-fundraise-1181626